EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Austria

Michael Guger iD, Robert Hatschenberger, Fritz Leutmezer

Brain and Behavior · 2023-04 · 13 (4)

DOI: 10.1002/brb3.2947 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Brain and Behavior, online erschienen am 19.03.2023. Verfasst von Michael Guger und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Pyhrn-Eisenwurzen Klinikum Steyr, Steyr, Austria. Hauptthemen laut MEDLINE: Multiple Sclerosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Randomized controlled trials and observational studies of nabiximols oromucosal spray in patients with multiple sclerosis (MS) spasticity have shown improvement in a range of associated symptoms (pain, spasms, fatigue, bladder dysfunction, and sleep disturbances). This study evaluated the effectiveness and tolerability of add‐on nabiximols in the routine management of patients with MS spasticity in Austria, with a focus on spasticity‐associated symptoms.

Methods

This was an open, prospective, multicenter, observational, non‐interventional study of patients with MS spasticity receiving add‐on treatment with nabiximols oromucosal spray. Main endpoints were patient‐reported changes from baseline in the frequency (counts) or severity (mean Numerical Rating Scale [NRS] scores) of spasticity‐associated symptoms, and patient‐reported changes from baseline in impairment of daily activities due to spasticity, after 1 and 3 months of nabiximols treatment. No analyses were conducted for statistical significance.

Results

There were 55 patients in the effectiveness population, and 62 in the safety population. Patients reported clinically relevant reductions from baseline to month 3 in the average number of spasms/day (−68.2%) and number of urinary incontinence episodes (−69.3%) in the week prior to the clinic visit, and reductions in mean 0−10 NRS scores for sleep impairment (−47.2%), fatigue (−26.4%), pain (40.4%), and spasticity severity (39.0%). There was no change from baseline in daily activity impairment due to spasticity. The majority of patients were at least partly satisfied with add‐on nabiximols for spasticity‐associated symptoms. There were 31 adverse events (27 treatment related) reported in 19 patients, with no new safety signals.

Conclusions

Add‐on nabiximols improved the severity of MS spasticity and a range of spasticity‐associated symptoms during real‐world use in Austria. Nabiximols is an option for patients with MS spasticity who fail first‐line oral antispasticity treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisHumansProspective StudiesAustriaMuscle SpasticityPainSpasmCannabidiolDrug CombinationsDronabinol

Stichwörter der Autor:innen

multiple sclerosisnabiximolsobservational studyspasticity-associated symptoms

Substanzen

nabiximolsCannabidiolDrug CombinationsDronabinol

Autor:innen und Institutionen

  • Department of Neurology, Pyhrn-Eisenwurzen Klinikum Steyr, Steyr, Austria.
  • Department of Neurology, Klinikum Bad Hall and Bad Schallerbach, Bad Schallerbach, Austria.
  • Department of Neurology, Medical University Vienna, Vienna, Austria.

ORCID-Profile: Michael Guger

Zitieren

APA

Guger, M., Hatschenberger, R., & Leutmezer, F. (2023). Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Austria. Brain and Behavior, 13(4). https://doi.org/10.1002/brb3.2947

Vancouver

Guger M, Hatschenberger R, Leutmezer F. Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Austria. Brain and Behavior. 2023;13(4). doi:10.1002/brb3.2947

BibTeX
@article{Guger2023,
  author = {Guger, Michael and Hatschenberger, Robert and Leutmezer, Fritz},
  title = {Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Austria},
  journal = {Brain and Behavior},
  year = {2023},
  volume = {13},
  number = {4},
  doi = {10.1002/brb3.2947}
}
Kostenlos starten →